Most Read Articles
Rachel Soon, 2 days ago

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Roshini Claire Anthony, 16 hours ago

The reduction in bleeding events with 12-month ticagrelor monotherapy after 3-month dual antiplatelet therapy (DAPT) among high-risk patients who have undergone percutaneous coronary intervention (PCI) in the TWILIGHT* trial is consistent among patients with diabetes mellitus (DM), the TWILIGHT-DM trial showed.

02 Apr 2020
Cabozantinib plus androgen deprivation therapy (ADT) shows potent clinical activity in hormone-naïve metastatic prostate cancer (HNMPCa), according to the results of a phase II trial.

Rituximab an acceptable biologic option for RA-associated bronchiectasis

25 Mar 2020

The use of rituximab in the treatment of rheumatoid arthritis (RA)-associated bronchiectasis (BR) helps stabilize or improve pulmonary symptoms, with a more favourable respiratory survival over a 5-year follow-up as compared with tumour necrosis factor inhibitors (TNFi), according to a retrospective study.

Researchers examined the medical records of 800 RA patients treated with rituximab, among whom 68 patients (mean age, 63 years; 71 percent female) had RA-BR (prevalence, 8.5 percent). After treatment with rituximab, new BR (evaluated as the number of infective exacerbations per year) occurred in only 3/735 patients (incidence, 0.4 percent) after 1.7 years of exposure and at least two treatment cycles.

At month 12 after the first cycle of rituximab, in the group of 68 patients with RA-BR at baseline, 21 (31 percent) experienced fewer exacerbations than the year prior to treatment, 36 (53 percent) remained stable, and 11 (16 percent) had increased exacerbations. The rates of exacerbation improved after the second treatment cycle and stabilized up to five cycles.

Of the 60 patients who received at least two rituximab cycles, seven (12 percent) had increased exacerbations and were associated with low immunoglobulin G, aspergillosis and concurrent alpha-1-antitrypsin deficiency.

The adjusted 5-year respiratory survival was better in rituximab-treated compared with TNFi-treated (n=46) RA-BR patients (hazard ratio, 0.40, 95 percent confidence interval, 0.17–0.96; p=0.041). Treatment was discontinued due to respiratory causes in eight patients in the rituximab group (11.8 percent) vs 15 patients in the TNFi group (32.6 percent).

The present data suggest that rituximab is an acceptable treatment choice for RA-BR patients, as well as support a definitive study of the drug for managing the condition from both an articular and a respiratory perspective, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 2 days ago

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Roshini Claire Anthony, 16 hours ago

The reduction in bleeding events with 12-month ticagrelor monotherapy after 3-month dual antiplatelet therapy (DAPT) among high-risk patients who have undergone percutaneous coronary intervention (PCI) in the TWILIGHT* trial is consistent among patients with diabetes mellitus (DM), the TWILIGHT-DM trial showed.

02 Apr 2020
Cabozantinib plus androgen deprivation therapy (ADT) shows potent clinical activity in hormone-naïve metastatic prostate cancer (HNMPCa), according to the results of a phase II trial.